Ignite Creation Date:
2024-05-06 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03507127
Status:
TERMINATED
Last Update Posted:
2022-05-17
First Post:
2018-04-05
Brief Title:
Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
Sponsor:
Brown University
Organization:
Brown University
Study Overview
Official Title:
Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
Status:
TERMINATED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low rate of enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Schizophrenia is associated with high rates of cigarette smoking and associated morbidity and mortality In this study smokers with schizophrenia will complete a baseline session and then randomized to varenicline VAR or placebo PLA After 1 week on medication participants will complete a cigarette rating task session Participants will then undergo a 72-hr abstinence period in which they will come to the laboratory twice per day and receive high-value cash reinforcement contingent upon meeting a strict breath CO abstinence criterion At each visit they will rate withdrawal symptoms mood and craving At the end of the abstinence period they will repeat the cigarette rating task Participants will return to the lab to provide a CO sample 24 hours later and will text the lab with videos of their CO samples for one week Date and time of smoking relapse will be measured from these samples
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None